Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

Respiratory Research

Table 2 Restricted or prohibited immunomodulatory or antifibrotic therapies taken at baseline, during treatment with trial drug and/or following discontinuation of trial drug over 52 weeks by customized drug grouping or preferred name

	Nintedanib (n = 332)	Placebo (n = 331)
≥ 1 restricted or prohibited therapy	53 (16.0)	91 (27.5)
Glucocorticoids^a	44 (13.3)	72 (21.8)
Mycophenolate mofetil	9 (2.7)	9 (2.7)
Azathioprine	4 (1.2)	6 (1.8)
Tacrolimus	4 (1.2)	5 (1.5)
Ciclosporin	1 (0.3)	6 (1.8)
Rituximab	3 (0.9)	2 (0.6)
Cyclophosphamide	0 (0.0)	3 (0.9)
Nintedanib^a	0 (0.0)	3 (0.9)
Pirfenidone^a	2 (0.6)	1 (0.3)

Data are n (%) of subjects who took ≥ 1 such therapy at baseline, during treatment with trial drug, and/or following discontinuation of trial drug (up to week 52) for any duration. Glucocorticoids were only counted as restricted therapies if used at high dose (> 20 mg/day prednisone or equivalent) and if the route of administration was oral, intravenous, intravenous bolus, intravenous drip, or intramuscular. Other therapies are displayed regardless of dose or route of administration
^aBased on customized drug grouping; for other therapies, preferred names are shown

ISSN: 1465-993X